Asia Pacific Influenza Vaccines Market Forecast to 2028 – COVID-19 Impact and Regional Analysis ­– by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Ce

Asia Pacific Influenza Vaccines Market Forecast to 2028 – COVID-19 Impact and Regional Analysis ­– by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-based), Route of Administration (Injection and Nasal Spray), and Target Group (Infants, Children, Adults, and Elderly People)

The Asia Pacific influenza vaccines market is expected to grow from US$ 1,688.07 million in 2022 to US$ 2,669.27 million by 2028; it is estimated to grow at a CAGR of 6.9% from 2022 to 2028.

Emerging Economies to Fuel Asia Pacific Influenza Vaccines Market During Forecast Period

Leading players in the Asia Pacific influenza vaccines market focus on expanding their customer reach across emerging markets by expanding their distribution networks and augmenting their manufacturing capabilities. With the maturing of the region, players are shifting their focus to emerging economies. Due to less stringent regulations and data requirements, Asia Pacific has become a business-friendly and adaptable hub. In addition, high investments in life science and healthcare research in emerging countries play a crucial role in upgrading the latest technologies in developing countries, which supports the inclination toward advanced vaccine development. Key producers of influenza vaccines in India and South Korea are expected to witness lucrative opportunities in the coming years due to the large patient pool and high prevalence of influenza, surge in healthcare infrastructure, rise in disposable income, and the surge of medical tourism in these countries.

Asia Pacific Influenza Vaccines Market Overview

Asia Pacific (APAC) is the fastest-growing regional market for influenza vaccines. The Asia Pacific influenza vaccines market is segmented into China, India, Japan, South Korea, Australia, and the Rest of APAC. Owing to the increase in government support and surveillance regarding vaccination against influenza, rise in investment by leading market players across the region, and increase in prevalence and incidence of influenza in this region. These factors are expected to propel the Asia Pacific influenza vaccines market in the coming years.

Asia Pacific Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Influenza Vaccines Market Segmentation

The Asia Pacific influenza vaccines market is segmented into vaccine type, virus type, technology, route of administration, target group, and country.

Based on vaccine type, the Asia Pacific influenza vaccines market is bifurcated into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered a larger share of the market in 2022.

Based on virus type, the Asia Pacific influenza vaccines market is bifurcated into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger share of the market in 2022.

Based on technology, the Asia Pacific influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger share of the market in 2022.

Based on route of administration, the Asia Pacific influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger share of the market in 2022.

Based on target group, the Asia Pacific influenza vaccines market is segmented into infants, children, adults, and elderly people. The infants segment held the largest share of the market in 2022.

Based on country, the Asia Pacific influenza vaccines market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China dominated the market in 2022.

AstraZeneca; Emergent BioSolutions Inc.; GlaxoSmithKline plc.; Hualan Biological Engineering Inc.; Mitsubishi Chemical Group Corporation; Moderna, Inc.; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the Asia Pacific influenza vaccines market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific influenza vaccines market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific influenza vaccines market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution